

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1-22. (Cancelled)

23. (Currently amended) A protein C or activated protein C polypeptide comprising a modified GLA domain, said modified GLA domain comprising ~~at least one amino acid substitution~~ the amino acid sequence of SEQ ID NO:1 with one, two, three, or four amino acid substitutions, wherein said substitutions are at positions selected from residues ~~11, 12, 29, and 34~~ 10, 11, 28, and 33.

24. (Currently amended) The protein C or activated protein C polypeptide of claim 23, wherein said ~~at least~~ one amino acid substitution is at residue ~~[[11]]~~ 10.

25. (Currently amended) The protein C or activated protein C polypeptide of claim 23, wherein said ~~at least~~ one amino acid substitution is at residue ~~[[12]]~~ 11.

26. (Currently amended) The protein C or activated protein C polypeptide of claim 23, wherein said ~~at least~~ one amino acid substitution is at residue ~~[[29]]~~ 28.

27. (Cancelled)

28. (Currently amended) The protein C or activated protein C polypeptide of claim 23, wherein said ~~at least~~ one amino acid substitution is at residue ~~[[34]]~~ 33.

29. (Currently amended) A protein C or activated protein C polypeptide comprising a modified GLA domain, said modified GLA domain comprising the amino acid sequence of SEQ

ID NO:1 with three amino acid substitutions, wherein said substitutions are at positions selected from the group consisting of residues ~~11, 12, 29, 33 and 34~~ 10, 11, 28, 32, and 33.

30. (Currently amended) The protein C or activated protein C polypeptide of claim 29, wherein said three amino acid substitutions are at residues ~~12, 33 and 34~~ 11, 32, and 33.

31. (Currently amended) The protein C or activated protein C polypeptide of claim [[29]] 30, wherein residue [[33]] 32 of SEQ ID NO:1 is glutamic acid.

32. (Currently amended) The protein C or activated protein C polypeptide of claim [[29]] 30, wherein residue [[34]] 33 of SEQ ID NO:1 is aspartic acid.

33. (Currently amended) The protein C or activated protein C polypeptide of claim [[29]] 30, wherein residue [[33]] 32 of SEQ ID NO:1 is glutamic acid and residue [[34]] 33 of SEQ ID NO:1 is aspartic acid.

34-42. (Cancelled)

43. (Currently amended) A protein C or activated protein C polypeptide comprising a modified GLA domain, said modified GLA domain comprising the amino acid sequence of SEQ ID NO:1 with four amino acid substitutions, wherein said substitutions are at positions selected from the group consisting of residues ~~11, 12, 29, 33 and 34~~ 10, 11, 28, 32, and 33.

44. (Currently amended) The protein C or activated protein C polypeptide of claim 43, wherein said four amino acid substitutions are at residues ~~11, 12, 33 and 34~~ 10, 11, 32, and 33.

45. (Currently amended) The protein C or activated protein C polypeptide of claim ~~[[43]] 44~~, wherein ~~said residue~~ residue [[11]] 10 of SEQ ID NO:1 is glutamine, residue ~~[[12]] 11~~ of SEQ ID NO:1 is glycine, residue ~~[[33]] 32~~ of SEQ ID NO:1 is glutamic acid, and residue ~~[[34]] 33~~ of SEQ ID NO:1 is aspartic acid.

46. (New) The protein C or activated protein C polypeptide of claim 23, further comprising a substitution at residue 32.

47. (New) The protein C or activated protein C polypeptide of claim 29, wherein residue 11 of SEQ ID NO:1 is glycine, residue 32 of SEQ ID NO:1 is glutamic acid, and residue 33 of SEQ ID NO:1 is aspartic acid.

48. (New) A pharmaceutical composition comprising said protein C or activated protein C polypeptide of any one of claims 23-26, 28-33, or 43-47 and a pharmaceutically acceptable carrier.

49. (New) The composition of claim 48 for use in treating thrombosis in a mammal.

50. (New) The composition of claim 48 for use in decreasing clot formation in a mammal.

51. (New) The composition of claim 49, wherein said composition is formulated for parenteral administration to a human patient.

52. (New) The composition of claim 50, wherein said composition is formulated for parenteral administration to a human patient.

53. (New) An isolated nucleic acid, said nucleic acid comprising a nucleic acid sequence encoding said protein C or activated protein C polypeptide of any one of claims 23, 29, or 43.

54. (New) A method of producing the protein C or activated protein C polypeptide of any one of claims 23-26, 28-33, or 43-47, said method comprising expressing an isolated nucleic acid encoding said protein C or activated protein C polypeptide in a mammalian host cell.

55. (New) The method of claim 54, wherein said mammalian host cell is an adenovirus-transfected human kidney 293 cell.